ISO 11607 1 2019 Amd 1 2023
ISO 11607 1 2019 Amd 1 2023
ISO 11607 1 2019 Amd 1 2023
STANDARD 11607-1
Second edition
2019-02
AMENDMENT 1
2023-09
Reference number
ISO 11607-1:2019/Amd.1:2023(E)
© ISO 2023
ISO 11607-1:2019/Amd.1:2023(E)
Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards
bodies (ISO member bodies). The work of preparing International Standards is normally carried out
through ISO technical committees. Each member body interested in a subject for which a technical
committee has been established has the right to be represented on that committee. International
organizations, governmental and non-governmental, in liaison with ISO, also take part in the work.
ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of
electrotechnical standardization.
The procedures used to develop this document and those intended for its further maintenance are
described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the
different types of ISO document should be noted. This document was drafted in accordance with the
editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).
ISO draws attention to the possibility that the implementation of this document may involve the use
of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed
patent rights in respect thereof. As of the date of publication of this document, ISO had not received
notice of (a) patent(s) which may be required to implement this document. However, implementers are
cautioned that this may not represent the latest information, which may be obtained from the patent
database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all
such patent rights.
Any trade name used in this document is information given for the convenience of users and does not
iTeh STANDARD PREVIEW
constitute an endorsement.
(standards.iteh.ai)
For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and
expressions related to conformity assessment, as well as information about ISO's adherence to
the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see
www.iso.org/iso/foreword.html.
ISO 11607-1:2019/Amd 1:2023
https://standards.iteh.ai/catalog/standards/sist/372cf871-e270-429a-a2df-32451256c64e/iso-
This document was prepared by Technical Committee ISO/TC 198, Sterilization of health care products,
in collaboration with the European 11607-1-2019-amd-1-2023
Committee for Standardization (CEN) Technical Committee CEN/
TC 102, Sterilizers for medical purposes, in accordance with the Agreement on technical cooperation
between ISO and CEN (Vienna Agreement).
A list of all parts in the ISO 11607 series can be found on the ISO website.
Any feedback or questions on this document should be directed to the user’s national standards body. A
complete listing of these bodies can be found at www.iso.org/members.html.
Clause 1, Scope
Delete the following text:
It is applicable to industry, to health care facilities, and to wherever medical devices are placed in
sterile barrier systems and sterilized.
3.7
iTeh STANDARD PREVIEW
Replace term and definition entry with the following:
3.7
(standards.iteh.ai)
labelling
label, instructions for use andISO any11607-1:2019/Amd
other information1:2023
that is related to identification, technical
description, intended purpose and proper use of the medical device, but excluding shipping documents
https://standards.iteh.ai/catalog/standards/sist/372cf871-e270-429a-a2df-32451256c64e/iso-
11607-1-2019-amd-1-2023
[SOURCE: ISO 13485:2016, 3.8]
Clause 3
Add the following term entries:
3.32
hazard
potential source of harm
[SOURCE: ISO/IEC Guide 63: 2019, 3.2]
3.33
intended use
intended purpose
use for which a product, process or service is intended according to the specifications, instructions and
information provided by the manufacturer
Note 1 to entry: The intended medical indication, patient population, part of the body or type of tissue interacted
with, user profile, use environment, and operating principle are typical elements of the intended use.
Note 2 to entry: "intended use" is used in the United States and "intended purpose" is used in the European
Union. These terms have essentially the same meaning. Throughout this document, the term "intended use" is
used.
[SOURCE: ISO/IEC Guide 63:2019, 3.4, modified — "intended purpose" was added to term, Note 2 to
entry was added.]
3.34
process
set of interrelated or interacting activities that use inputs to deliver an intended result
Note 1 to entry: Whether the "intended result" of a process is called output, product or service depends on the
context of the reference.
Note 2 to entry: Inputs to a process are generally the outputs of other processes and outputs of a process are
generally the inputs to other processes.
Note 3 to entry: Two or more interrelated and interacting processes in series can also be referred to as a process.
[SOURCE: ISO 9000:2015, 3.4.1, modified — Notes to entry 4, 5 and 6 have been deleted]
3.35
reasonably foreseeable misuse
use of a product or system in a way not intended by the manufacturer, but which can result from readily
predictable human behaviour
Note 1 to entry: Readily predictable human behaviour includes the behaviour of all types of users, e.g. lay and
professional users.
4.4.3, NOTE
Replace with the following:
NOTE Annex B contains a list of test methods. Publication of a method by a standards body
does not make it validated by the user of the test method.
6.1.1
Replace the text with the following:
6.1.1 The packaging system shall be designed to minimize the risks, as specified in Annex F, to the
user and patient during intended use and/or reasonably foreseeable misuse.
NOTE See also 4.2 as well as Annex G for guidance on packaging risk management.
Bibliography
Add the following entries to the Bibliography:
[170] ISO/TR 24971, Medical devices — Guidance on the application of ISO 14971
[171] ISO/IEC Guide 63:2019, Guide to the development and inclusion of aspects of safety in International
Standards for medical devices
[172] ISO 9000:2015, Quality management systems — Fundamentals and vocabulary
Annex F, Annex G
Add the following new Annexes F and G after Annex E.
Annex F
(normative)
Risk management
b) Validation phase
— Performance and stability testing (see Clause 8 and G.2.8.3);
— Usability evaluation (see Clause 7 and G.2.8.2).
NOTE Process validation is addressed in G.2.8.4 and ISO 11607-2.
c) Production phase
— Packaging system changes (see Clause 9 and G.2.10).
NOTE Process control and monitoring, assembly, use of reusable sterile barrier systems, process
changes and revalidation are addressed in ISO 11607-2 and G.2.9.
d) Post-production phase
— If post-production information is available on the performance of the packaging system, it
shall be analysed to determine if risks are controlled appropriately or if unidentified hazards
or hazardous situations are present. Consequent corrective and preventive actions shall be
implemented as needed.
NOTE 1 The corrective and preventive actions can include redesign, additional controls or
revalidation.
NOTE 2 This document does not include requirements for collecting post-production
information or for reporting adverse events and field safety corrective actions to authorities or other
related activities. This is typically established based on the requirements of the quality management
system.
NOTE
iTeh STANDARD PREVIEW
Mix-ups (e.g. incorrect label, wrong file or information, data)
For further guidance see G.2.2 on hazards to be addressed, G.2.3 on identification of sequences of
(standards.iteh.ai)
events and G.2.4 on related hazardous situations. Table G.1 provides examples of relationship between hazards,
foreseeable sequences of events and resulting hazardous situations.
Risk control in packaging system design for terminally sterilized medical devices shall be based on the
following principles in the priority order listed:
a) Eliminate or reduce risks to an acceptable level through safe design. A packaging system (inclusive
of sterile barrier system and protective packaging), is considered inherently safe by design for
assurance of sterility when it meets the requirements below without additional measures.
— Allow for sterilization (see 6.1.5).
— Provide physical protection to maintain SBS integrity (see 6.1.3) for expected conditions and
hazards during the specified processing, storage, handling, and distribution until that SBS is
opened at the point of use (see 6.1.6).
— Allow for the aseptic opening of the SBS and presentation of its contents (see 6.1.2).
NOTE 1 The term “safe” in this context indicates the state where the risks from recognized
hazardous situations have been reduced to an acceptable level (see ISO Guide 63:2019).
NOTE 2 ISO 11607-1 provides the state-of-art approach to validate packaging for assurance
of sterility, i.e. to reduce the risk of microbial contamination. In addition to the control of microbial
contamination hazards for assurance of sterility, further hazards and risks must be considered
where the state-of-art approach will be provided by other standards, e.g. ISO 10993-1 for chemical
contamination and biocompatibility aspects.
b) Take adequate measures in relation to risks that cannot be eliminated, for example, shipping
controls.
NOTE iTeh STANDARD PREVIEW
An example of shipping controls would be the use of a temperature or humidity indicator for
(standards.iteh.ai)
either a device or packaging, or both, that can be adversely affected by potential extreme temperature or
high humidity exposures in transport.